Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. - Wikidata - wikimedia - TriplyDB

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

http://www.wikidata.org/entity/Q30313824

about

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

P2860

Q46185591-475050BA-4D89-4322-A43F-748072B5462F

P2860

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

http://www.wikidata.org/entity/Q30313824

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@ast

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@en

type

label

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@ast

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@en

prefLabel

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@ast

Dalotuzumab in chemorefractory ...... randomised phase II/III trial.

@en

P1433

Q30313824-C142C194-2C03-423B-8A34-EA0EE5B4BE74

P1476

Q30313824-7E866779-9942-42C7-B6A8-9B2BB7F50991

P2093

Q30313824-0D5B521A-F129-4947-8CBA-5C9571391460

Q30313824-0F66A9AD-3B9B-4A9A-BF44-B27624345B66

Q30313824-10CC6932-A47A-4F38-8A94-34A3FDD40A1E

Q30313824-26B0A1B1-568A-44F2-920D-C244126774C6

Q30313824-30C47DB5-500A-45C8-8CF0-F29C65B874C3

Q30313824-428CF1EB-1E68-4CE7-9581-3CC441495FD8

Q30313824-4B01C92F-8161-49E1-86AB-85094CC670A0

Q30313824-4EF3A9D5-1458-4C87-8A85-7F4A0025EF2A

Q30313824-6CAFDEF9-0AD0-4EAC-8CCC-D1D0FC2754BE

Q30313824-869642EA-530E-4C76-9866-14C5F3700DF0

P2860

Q30313824-0164AC74-42E7-47BD-A62C-521321E18115

Q30313824-02B65161-A55D-468E-BE6E-2FB1BC1BA259

Q30313824-03A551D9-095B-4F33-B9A5-C5C9F08E7646

Q30313824-076A7222-54C4-4C79-BC84-6EEB5B49F4B4

Q30313824-0A7304AD-1FA8-4047-A5A8-D65922C0E10D

Q30313824-0E770F1A-33DB-4614-8F99-97DF445FAAEE

Q30313824-11368951-F127-48C7-85C0-BDD6EEF9FB21

Q30313824-177E61B5-DB57-463E-ACD5-7949E65B459E

Q30313824-18425E25-41D4-4859-B37A-8C3948B64235

Q30313824-268812E7-3F0D-4DD6-90F7-468D147B52AB

P304

Q30313824-1FC8144E-AB7F-4DAD-9388-41CCAAF6B007

P31

Q30313824-DE1E4607-598A-4E0A-8F29-F5DEB8B3E722

P356

Q30313824-BC9F02ED-F135-4C80-8EFA-1107A38B2C68

P433

Q30313824-189C1DF2-E625-43D3-AD94-93E0B1A568C3

P478

Q30313824-907ABB84-2579-4B4E-8E9E-89E1E1F99C98

P50

Q30313824-26626E36-6723-4CFC-89DC-39B203E991F5

Q30313824-C2038419-22D8-478F-A9E2-8A0B2075C91F

Q30313824-E5EA1AB6-2A55-44E3-B869-C656CA7D5231

P577

Q30313824-6B513CE0-2968-427E-859C-21BD97E59A2A

P698

Q30313824-5AD9749F-6D4E-4AA3-9CA0-DEBCFC5B95FA

P921

Q30313824-093F0C39-6F94-4C2C-89CB-64755A4EB7B7

Q30313824-6F20FE28-210C-4442-BE00-A48FABA27228

Q30313824-8CD77A12-6A06-4FF9-BCE1-60561B679E4E

P356

P1433

International Journal of Cancer

P1476

Dalotuzumab in chemorefractory ...... randomised phase II/III trial

@en

P2093

Andrey Loboda

http://www.w3.org/2001/XMLSchema#string

Clare Peckitt

http://www.w3.org/2001/XMLSchema#string

David Ferry

http://www.w3.org/2001/XMLSchema#string

David J Watkins

http://www.w3.org/2001/XMLSchema#string

Francesco Sclafani

http://www.w3.org/2001/XMLSchema#string

Hans J Schmoll

http://www.w3.org/2001/XMLSchema#string

Jae K Roh

http://www.w3.org/2001/XMLSchema#string

Jan-Erik Frodin

http://www.w3.org/2001/XMLSchema#string

Mark Ayers

http://www.w3.org/2001/XMLSchema#string

Michael Nebozhyn

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis.

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Insulin-like growth factors and neoplasia.

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

P304

431-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.30453

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

David Cunningham

P577

2016-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27681944

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase II clinical trial

phase III clinical trial